Evidence map›Paper›PMID 30261942›Full record

ArticleBJPsych bulletin2019

Barriers to using clozapine in treatment-resistant schizophrenia: systematic review.

Saeed Farooq, Abid Choudry, Dan Cohen, Farooq Naeem, Muhammad Ayub

Open access · diamondAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in BJPsych bulletin, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 87 papers, 7 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
87citing papers in PubMed, 7 pooled it
8.9field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

87 citing papers in PubMed, 7 syntheses or guidelines pooled it, 169 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Guideline
  6. Pooled it
  7. Pooled it
  8. Trial
  9. Article
  10. Observational
  11. Article
  12. Review
  13. Article
  14. Clozapine-induced Myocarditis in Korea: Analysis of a Nationwide Database and Comparison to Other Countries.Clinical psychopharmacology and neuroscience : the official scientific journal of the Korean College of Neuropsychopharmacology · 2026
    Article
  15. Review
  16. Article
  17. Article
  18. Article
  19. Review
  20. Article

27 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 4 institutions in 3 countries.

Saeed FarooqKeele University,UK.
Abid ChoudryBirmingham Women's and Children's NHS Foundation Trust,UK.ORCID http://orcid.org/0000-0002-7721-1602
Dan CohenMental Health Organization North-Holland North Heerhugowaard,The Netherlands.
Farooq NaeemQueen's University,Kingston,Canada.
Muhammad AyubQueen's University,Kingston,Canada.
Queen's University · CABirmingham Women’s and Children’s NHS Foundation Trust · GBGGZ Noord-Holland-Noord · NLKeele University · GB

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Aims and methodTo systematically review the literature on barriers to the use of clozapine and identify any interventions for optimizing clozapine use in treatment-resistant schizophrenia. Journal databases were searched from 1972 to March 2018. The following search terms were used: treatment-resistant schizophrenia, clozapine, barriers, use, prescription rates, implementation, clozaril and prescribing practices. Following a review of the literature, 15 papers were included in the review.

resultsThe major barriers that were identified included mandatory blood testing, fear of serious side-effects and lack of adherence by the patients, difficulty in identifying suitable patients, service fragmentation, and inadequate training in or exposure to using clozapine.Clinical implicationsIn view of consistent evidence across the studies on inadequate knowledge and skills as a significant barrier, we suggest that a certification requiring competence in initiating and managing side-effects of clozapine becomes a mandatory requirement in training programmes.Declarations of interestNone.

Indexed as

barriersclozapineTreatment resistant schizophrenia

Identifiers

PMID30261942
PMCPMC6327301
OpenAlexW2893591395

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.